GleamWall
中文EN

LEEEF Leef Brands Inc.

Medicinal Chemicals & Botanical Products · OTC · SEC CIK 1711141 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin42.1%
Operating margin-16.3%
Net margin-38.2%
FCF margin-23.4%
EBITDA margin-12.3%

Returns

ROE—
ROA—
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets92.5%
Debt / equity0.00x
Current ratio2.24x
Interest coverage-3.95x

Cash quality & payout

Operating cash flow / net income0.40x
Accruals ratio—
Payout ratio—
Capex / revenue8.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-31
Income statement
Revenue$8.07M$7.27M$9.38M$8.32M$8.38M$8.69M$9.40M
Cost of revenue$4.99M$4.86M$4.75M$4.53M$5.25M$7.20M$7.32M
Gross profit$3.08M$2.41M$4.62M$3.79M$3.13M$1.49M$2.07M
R&D expense$4,565$6,281$2,081$0$498$10,570$8,628
SG&A expense$802,872$705,705$601,591$917,531$673,641$733,569$797,417
Operating income-$1.51M-$1.99M$1.28M-$3.17M-$135,801-$2.37M-$1.91M
Interest expense$244,511$242,195$316,834$559,087$635,385$579,387$592,501
Pretax income$337,954-$630,698$548,327-$11.01M-$2.77M-$2.33M$986,889
Income tax$56,013$704,050$974,580$151,548$1.04M$607,891$721,113
Net income$281,941-$1.33M-$426,253-$11.16M-$3.80M-$2.93M$265,776
EBITDA-$1.16M-$1.64M$1.57M-$2.84M$195,022-$2.07M-$1.61M
EPS (basic)0.00-0.01-0.00—-0.02-0.020.00
EPS (diluted)0.00-0.01-0.00—-0.02-0.020.00
Weighted avg. shares (diluted)305.56M290.00M259.68M—180.72M175.44M266.66M
Balance sheet
Cash & equivalents$5.90M$4.95M$5.76M$2.19M———
Receivables$2.99M$2.21M$2.63M$1.59M———
Inventory$8.34M$7.15M$3.59M$3.35M———
Current assets$19.52M$16.37M$13.74M$8.15M———
PP&E, net$26.25M$25.55M$24.98M$25.04M———
Goodwill$6.05M$6.05M—$0———
Intangibles$2.23M$2.34M$1.08M$1.12M———
Total assets$56.07M$52.41M$41.85M$36.40M———
Current liabilities$8.73M$7.69M$7.85M$8.35M———
Total liabilities$51.86M$54.45M$47.60M$44.67M———
Shareholders' equity$4.21M-$2.04M-$5.75M-$8.27M-$16.22M-$13.08M-$10.64M
Shares outstanding305.56M305.56M265.96M257.95M———
Cash flow statement
Operating cash flow-$2.74M-$4.07M$395,001$1.35M$350,683-$197,176-$1.84M
Capital expenditure$987,178$1.15M$494,839$27,329$126,805$325,805$162,075
Free cash flow-$3.73M-$5.21M-$99,838$1.32M$223,878-$522,981-$2.00M
Investing cash flow-$987,178-$943,912-$494,839-$166,846-$198,119-$222,183-$162,075
Financing cash flow$4.68M$4.20M$3.67M-$904,542$875,845$391,998$181,903
Depreciation & amortization$352,639$350,235$285,490$330,865$330,823$304,107$294,503
Stock-based compensation$649,839$700,153$489,467$1.25M$350,153$492,423$591,462
Dividends paid$90,506——————

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.